The potential of the combined use of targeted type I interferon pathway inhibitors and oncolytic viruses to treat sarcomas.
Vet Comp Oncol
; 18(1): 36-42, 2020 Mar.
Article
em En
| MEDLINE
| ID: mdl-31618515
ABSTRACT
Replicating oncolytic viruses (OVs) are appealing, new, FDA-approved, therapeutic options for humans with head and neck cancers and melanomas. These treatments are not yet available for veterinary patients, but recent clinical trials have shown several OVs to be safe in dogs and cats. Specific viruses being used to treat sarcomas in dogs include modified canine adenovirus 2, myxoma virus, vesicular stomatitis virus and reovirus. In cats with vaccine-associated sarcomas, poxviruses have been injected postoperatively and a reduced rate of tumour recurrence was documented. To date, the response rates of canine and feline patients to OV therapy have been variable (as they are in people). Optimal methods of OV administration and dosing schedules continue to be evaluated. One way to improve outcomes of OV therapy in veterinary patients may be to use OVs in combination with other immunomodulatory therapies. This review discusses the potential utility of concurrent therapy with an OV and an inhibitor of the type I interferon pathway.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Temas:
Geral
/
Tipos_de_cancer
/
Outros_tipos
Base de dados:
MEDLINE
Assunto principal:
Sarcoma
/
Neoplasias de Tecidos Moles
/
Doenças do Gato
/
Interferon Tipo I
/
Doenças do Cão
/
Terapia Viral Oncolítica
/
Antineoplásicos
Limite:
Animals
Idioma:
En
Revista:
Vet Comp Oncol
Assunto da revista:
MEDICINA VETERINARIA
/
NEOPLASIAS
Ano de publicação:
2020
Tipo de documento:
Article